Table 1.
Patient characteristics among the 433 patients that had both blood-derived ctDNA and tissue testing done
| Patient characteristics | Total patients n = 433 |
|---|---|
| Age at diagnosis (years: median, range) | 59 (2–91) |
| Gender (n, %) | |
| Women | 237 (54.7%) |
| Men | 196 (45.3%) |
| Type of cancer (n, %) | |
| Gastrointestinal1 | 104 (24.0%) |
| Lung | 78 (18.0%) |
| Brain | 56 (12.9%) |
| Breast | 50 (11.5%) |
| Hepatic/pancreatic/biliary | 40 (9.2%) |
| Head and neck | 31 (7.2%) |
| Gynecologic | 22 (5.1%) |
| Others2 | 52 (12.0%) |
| Tissue biopsy site (n, %) | |
| Liver | 63 (14.5%) |
| Brain | 59 (13.6%) |
| Lung | 54 (12.5%) |
| Gastrointestinal | 51 (11.8%) |
| Lymph node | 18 (4.2%) |
| Breast | 13 (3.0%) |
| Gynecologic | 13 (3.0%) |
| Others | 162 (37.4%) |
| Time between tissue biopsy and blood draw for ctDNA | |
| Median months (interquartile range) | 5.0 (0.03–241) |
| Category (n, %) | |
| ≤2 months | 165 (38.1%) |
| >2 to 6 months | 69 (15.9%) |
| >6 months | 199 (46.0%) |
1
Includes colorectal cancer (n = 54), appendiceal cancer (n = 20), gastric cancer (n = 8), esophageal cancer (n = 7), gastrointestinal stromal tumor (n = 7), anal cancer (n = 3), small bowel cancer (n = 3), and neuroendocrine tumor (n = 2).
2
Includes genitourinary/prostate cancers (n = 16), cancers of unknown primary (n = 10), soft tissue sarcoma (n = 8), hematologic malignancies (n = 7), mesothelioma/peritoneal carcinoma (n = 5), skin carcinoma (n = 4), and thymoma (n = 2).